Media Articles Related to Zelboraf (Vemurafenib)
Drug combination for advanced melanoma wins FDA approval
Source: Dermatology News From Medical News Today [2015.11.12]
US regulators have approved a drug combination - vemurafenib (Zelboraf) and cobimetinib (Cotellic) - for advanced melanoma that shows great promise in extending patients' lives.
Acute Kidney Injury Linked to BRAF Inhibitors in Melanoma
Source: Medscape Nephrology Headlines [2015.11.17]
Treatment with vemurafenib and dabrafenib was associated with acute renal toxicity in patients with melanoma, according to data from the FDA Adverse Event Reporting System.
Medscape Medical News
FDA approves Cotellic as part of combination treatment for advanced melanoma
Source: Dermatology News From Medical News Today [2015.11.11]
The U.S. Food and Drug Administration has approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't...
Published Studies Related to Zelboraf (Vemurafenib)
A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of
vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. 
microprecipitated bulk powder film-coated tablets)... CONCLUSIONS: Vemurafenib plasma concentration accumulates with multiple bid doses
Combination of vemurafenib and cobimetinib in patients with advanced
BRAF(V600)-mutated melanoma: a phase 1b study. 
MEK inhibition with cobimetinib in patients with advanced BRAF-mutated melanoma... INTERPRETATION: The combination of vemurafenib and cobimetinib was safe and
Vemurafenib for the treatment of locally advanced or metastatic BRAF V600
mutation-positive malignant melanoma: a NICE single technology appraisal. 
Vemurafenib is an oral BRAF inhibitor licenced for the treatment of locally
advanced or metastatic BRAF V600-mutation positive malignant melanoma. The
manufacturer of vemurafenib, Roche Products Limited, was invited by the National
Institute for Health and Care Excellence (NICE) to submit evidence of the drug's
clinical- and cost-effectiveness for its licenced indication, to inform the
Institute's Single Technology Appraisal (STA) process...
Vemurafenib and ipilimumab: new agents for metastatic melanoma. 
CONCLUSION: Vemurafenib and ipilimumab are important advances in the treatment of
Analysis of dermatologic events in vemurafenib-treated patients with melanoma. 
carcinoma (cuSCC)... CONCLUSIONS: Dermatologic AEs associated with vemurafenib treatment in patients
Clinical Trials Related to Zelboraf (Vemurafenib)
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer [Recruiting]
The goal of this clinical research study is to learn about how vemurafenib may affect
certain biomarkers in patients with PTC. Biomarkers are in the blood/tissue and may be
related to your reaction to the study drug. The safety of this drug will also be studied.
Vemurafenib is designed to block the BRAF gene mutation. This mutation causes cancer and
cancer growth. By blocking this mutation, the drug may kill the cancer cells with the
mutation and/or stop the tumor from growing.
The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolafï¿½) in Advanced Patients Harboring the V600 BRAF Mutation [Active, not recruiting]
The safety and efficacy study of Vemurafenib (CT) compared with Vemurafenib (Zelbolaf®)
Advanced patients carrying the V600E BRAF mutation.
Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas [Recruiting]
This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a
recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory
gliomas containing the BRAFV600E mutation.
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma [Terminated]
The purpose of the phase 1 portion of the study is to determine the maximally tolerated dose
(MTD) or recommended dose (RD) and the safety/tolerability of PX-866 in combination
vemurafenib in patients with any advanced BRAF-mutant cancer.
The purpose of the phase 2 portion of the study is to compare progression free survival
(PFS), antitumor activity (response rate), disease control rate (DCR), and the safety and
tolerability of PX-866 in combination with vemurafenib vs. vemurafenib alone in patients
with advanced BRAF-mutant melanoma at the doses recommended from Phase 1.
Study of Vemurafenib, Carboplatin, and Paclitaxel [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of
vemurafenib that can be given in combination with carboplatin and paclitaxel patients with
advanced cancer. The safety of the study drug combination will also be studied.
Vemurafenib is designed to block a protein (called mutated BRAF) that is only found in moles
(spots) of the skin and certain types of cancer cells. This drug may slow the growth of or
kill these cells.
Carboplatin is designed to slow the growth of cancer cells by stopping them from making new
DNA (the genetic material of cells).
Paclitaxel is designed to slow the growth of cancer cells by stopping them from dividing
into new cells.
Reports of Suspected Zelboraf (Vemurafenib) Side Effects
Decreased Appetite (106),
Disease Progression (73),
Diarrhoea (66), more >>